SDGR · Schrodinger, Inc.
$14.97
+0.07% last session
End-of-day data · updated 2026-07-28
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-9.2
Dividend yield
—
Beta
1.62
Avg volume
1M
Employees
1K
2D change
—
5D change
0.99%
10D change
-0.26%
30D change
-9.37%
60D change
0.53%
MTD change
-6.77%
YTD change
-14.54%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SDGR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-14
Latest call per bank · past 12 months
Morgan Stanley
Equal-Weight$17.00
+13.6% vs priceUBS
Neutral$13.00
-13.2% vs priceBank of America
Buy$24.00
+60.3% vs priceGoldman Sachs
Neutral$19.00
+26.9% vs priceCitigroup
Neutral$20.00
+33.6% vs priceBarclays
Overweight$25.00
+67.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-14 | Morgan Stanley | Maintains | Equal-Weight | $19.00 → $17.00 |
| 2026-04-08 | Keybanc | Maintains | Overweight | $25.00 → $20.00 |
| 2026-03-17 | UBS | Maintains | Neutral | $18.00 → $13.00 |
| 2026-01-08 | TD Cowen | Maintains | Buy | $33.00 → $24.00 |
| 2026-01-08 | Keybanc | Maintains | Overweight | $28.00 → $25.00 |
| 2026-01-07 | UBS | Initiates | Neutral | $0.00 → $18.00 |
| 2025-12-15 | Bank of America | Upgrade | Neutral → Buy | $24.00 |
| 2025-10-08 | Keybanc | Maintains | Overweight | $30.00 → $28.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.5% above the 50-day MA ($15.07).
- Price vs 200-day MA: Trading 0.1% below the 200-day MA ($15.31).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.17) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($11.07) and high ($22.52).
SDGR Price Chart
Loading chart for SDGR…
Fundamentals
About Schrodinger, Inc.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
More in Health Information Services
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.